A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein

This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.

开始日期2024-05-15

申办/合作机构

Tourmaline Bio, Inc.

NCT06088979

/ Recruiting临床2期

A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants With Thyroid Eye Disease

Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.

开始日期2024-02-19

申办/合作机构

Tourmaline Bio, Inc.

NCT01287897

/ Completed临床2期

A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Crohn's Disease Who Are Anti-tnf Inadequate Responders (Andante)

This is a proof of concept study to determine the efficacy and safety of a monoclonal antibody with three doses versus placebo. Subjects will be randomized to a treatment and the dose will be delivered subcutaneously twice, 4 weeks apart. All subjects will have moderate to severe refractory Crohn's Disease.

开始日期2011-02-01

申办/合作机构

Pfizer Inc.

100 项与 Pacibekitug 相关的临床结果

登录后查看更多信息

100 项与 Pacibekitug 相关的转化医学

登录后查看更多信息

100 项与 Pacibekitug 相关的专利（医药）

登录后查看更多信息

项与 Pacibekitug 相关的文献（医药）

2019-01-01·Gut1区 · 医学

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

1区 · 医学

Article

作者: Hellstern, Paul ; Kohn, Anna ; Panaccione, Remo ; Cataldi, Fabio ; Fraser, Gerald ; Rogler, Gerhard ; Maguire, Mary K ; Comer, Gail M ; Beebe, Jean ; Banerjee, Anindita ; Rath, Natalie ; Leong, Rupert W ; Vermeire, Séverine ; Li, Cheryl ; Desreumaux, Pierre ; Schreiber, Stefan ; Danese, Silvio

Objective:

Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.

Design:

Parallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After induction, patients entered 28-week follow-up or 48-week open-label extension (OLE) with 28-week follow-up. Adults with confirmed CD and inadequate response to anti-tumour necrosis factor (TNF) therapy were included. Induction study: 249 patients randomised 1:1:1:1 to placebo, PF-04236921 10, 50 or 200 mg by subcutaneous injection on days 1 and 28. OLE study: PF-04236921 50 mg every 8 weeks up to six doses followed by 28-week follow-up.

Results:

247 patients were randomised and received treatment in the induction study. The 200 mg dose was discontinued due to safety findings in another study (NCT01405196) and was not included in the primary efficacy analysis. Crohn’s Disease Activity Index (CDAI)-70 response rates with PF-04236921 50 mg were significantly greater than placebo at weeks 8 (49.3% vs 30.6%, P<0.05) and 12 (47.4% vs 28.6%, P<0.05) and met the primary end point. Week 12 CDAI remission rates with PF-04236921 50 mg and placebo were 27.4% and 10.9%, respectively (16.5% difference; P<0.05). 191 subjects received treatment in the OLE. Common treatment-emergent and serious adverse events in both studies included worsening CD, abdominal pain and nasopharyngitis.

Conclusions:

PF-04236921 50 mg induced clinical response and remission in refractory patients with moderate-to-severe CD following failure of anti-TNF therapy. GI abscess and perforation were observed, a specific focus of attention during future clinical development.

Trial registration number:

NCT01287897 and NCT01345318.

2017-03-01·Annals of the rheumatic diseases1区 · 医学

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

1区 · 医学

Article

作者: Diehl, Annette ; Eimon, Alicia ; Sridharan, Sudhakar ; Merrill, Joan T ; Petri, Michelle ; Healey, Paul ; Strand, Vibeke ; Wajdula, Joseph ; Beebe, Jean ; Li, Cheryl ; Christensen, Jared ; Spindler, Alberto J ; Popa, Serghei ; Wallace, Daniel J ; Vincent, Michael S ; Smolen, Josef S

Objectives:

This phase II trial evaluated the efficacy and safety of an interleukin (IL) 6 monoclonal antibody for systemic lupus erythematosus (SLE).

Methods:

Patients with active disease were randomised to placebo or PF-04236921 10 mg, 50 mg or 200 mg, subcutaneously, every 8 weeks with stable background therapy. SLE Responder Index (SRI-4; primary end point) and British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) were assessed at week 24. Post hoc analysis identified an enriched population based upon planned univariate analyses.

Results:

183 patients received treatment (placebo, n=45; 10 mg, n=45; 50 mg, n=47; 200 mg, n=46). The 200 mg dose was discontinued due to safety findings and not included in the primary efficacy analysis. The SRI-4 response rates were not significant for any dose compared with placebo; however, the BICLA response rate was significant for 10 mg (p=0.026). The incidence of severe flares was significantly reduced with 10 mg (n=0) and 50 mg (n=2) combined versus placebo (n=8; p<0.01). In patients with greater baseline disease activity (enriched population), the SRI-4 (p=0.004) and BICLA (p=0.012) response rates were significantly different with 10 mg versus placebo. Four deaths (200 mg, n=3; 10 mg, n=1) occurred. The most frequently reported adverse events included headache, nausea and diarrhoea.

Conclusions:

PF-04236921 was not significantly different from placebo for the primary efficacy end point in patients with SLE. Evidence of an effect with 10 mg was seen in a post hoc analysis. Safety was acceptable for doses up to 50 mg as the 200 mg dose was discontinued due to safety findings.

Trial registration number:

NCT01405196; Pre-results.

Frontiers in immunology

Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn’s Disease

Review

作者: Wang, Xiaoling ; Zhao, Libo ; Yu, Boran ; Jin, Siyao ; He, Huan ; Zhang, Jing

Information on comparative drug efficacy is of great importance for drug development as well as clinical practice. Up to now, the relative efficacy of biologics and small targeted molecules for Crohn’s disease (CD) remains unclear. The objective of this study was to quantify the relative efficacy of investigational and approved biological treatments for CD measured in Crohn’s Disease Activity Index (CDAI), Inflammatory Bowel Disease Questionnaire (IBDQ), and C-reactive protein (CRP). The analysis dataset was composed of summary-level data from 46 trials, containing 12,846 patients, with treatment of 24 drugs. Six mathematical models with non-parametric placebo estimations were developed to describe the time course and dose–response of six efficacy measures. The effects of covariate were further evaluated. Time–response relationships were found in outcomes measured in CDAI. The patients’ age, disease duration, baseline CDAI, and CRP showed an impact on the efficacy. Model simulations were performed to compare the efficacies across different drugs. The most achievement in clinical remission (defined as CDAI less than 150) and clinical response (defined as the reduction in CDAI for 100 or 70) was observed in the simulation for PF-04236921 and infliximab, respectively. The most improvement in IBDQ was shown in tofacitinib. In general, tumor necrosis factor (TNF)-α inhibitors were the most effective biologics, and the highest efficacy of small targeted molecules was observed in janus kinase (JAK) inhibitors. These findings have important implications for clinical practice in CD.

项与 Pacibekitug 相关的新闻（医药）

2025-09-11

·CPHI制药在线

“捡漏”辉瑞弃子？诺华14亿美元收购Tourmaline加固CRM管线

关注并星标CPHI制药在线 9月9日，诺华宣布已经达成协议，将以每股48美元的现金收购美国临床阶段生物技术公司Tourmaline Bio，整个交易估值大约在14亿美元左右。这次收购最核心的资产，是Tourmaline的主要候选药物pacibekitug。这款药物最初由辉瑞开发，但在2022年授权给了Tourmaline Bio，如今随着诺华的高价收购，这个曾经的"辉瑞弃子"价值获得了肯定。图源：诺华官网一、交易细节与市场反应这笔收购目前已经得到两家公司董事会的一致同意，诺华将会通过旗下一家间接全资子公司，对Tourmaline所有已发行的普通股发起要约收购，预计将于2025年第四季度完成。每股48美元的收购价格比Tourmaline Bio在9月8日的收盘价溢价59%，比其60天成交量加权平均股价更是溢价高达127%。消息一出，Tourmaline的股价一下子涨了超过57%，创下三年来的新高，收盘报47.62美元，已经很接近诺华的收购价。看得出来，市场普遍认为这笔交易最终成交的可能性非常大。二、Pacibekitug，从"弃子"到"宠儿" Pacibekitug是一种研究性的抗IL-6 IgG2人单克隆抗体，旨在减轻动脉粥样硬化性心血管疾病（ASCVD）中涉及的全身炎症，该药物已证明与IL-6具有高亲和力结合。 IL-6（白细胞介素-6）是一种多效性细胞因子，在炎症反应以及细胞和体液免疫中发挥关键作用，它是促进全身炎症的关键上游细胞因子，从而解决了一个关键的未满足的需求。今年5月22日，Tourmaline公布了pacibekitug的2期TRANQUILITY临床试验顶线结果。研究显示，与安慰剂相比，所有pacibekitug治疗组在第90天均实现了快速、显著且持久的hs-CRP水平降低，具有高度统计学意义。在每季度一次50mg给药组中，hs-CRP平均降低幅度超过85%。pacibekitug成为首个在每季给药频率下可显著降低hs-CRP水平的IL-6抑制剂。这一数据虽然最初被投资者拿来与诺和诺德的IL-6单抗ziltivekimab对比，后者在中期RESCUE试验中使hsCRP水平平均降低92%，导致Tourmaline股价一度大跌18%。但后来大家逐渐意识到，pacibekitug的优势在于只需每季度用药一次，更加方便，股价最终反弹，收盘时还涨了4%。 Tourmaline的科学价值之所以重估得益于其临床数据的可靠性和差异化优势，安全性数据也较为理想，pacibekitug组任何严重不良事件（AE）的累积发生率为10%，而安慰剂组为11%。 Tourmaline Bio的研究首次证明了季度给药的IL-6抑制剂在临床试验中的可行性，这种方便的给药方案可能成为该药物的一大竞争优势。目前还没有广泛采用的抗炎疗法可用于降低心血管风险。Pacibekitug有望填补这一空白，解决ASCVD治疗中的残余炎症风险。三、诺华为什么要收购Tourmaline？诺华近年来正在经历"去多元化"的深度转型。心血管-肾脏-代谢业务（CRM）是诺华四大核心治疗领域之一，2025年上半年实现收入同比增长26% 至51.73亿美元，成为公司第二大收入来源。诺华的重磅心衰药物沙库巴曲缬沙坦在2025年上半年实现销售额同比增长22%至46.18亿美元，但面临增长乏力困境。加之Entresto专利到期、仿制药很快会进入美国市场，诺华必须未雨绸缪。再者，心血管疾病的发病率仍在持续上升，市场对相关药物的需求一直很大，竞争也异常激烈。辉瑞、默克这些大药企都在心血管领域有所布局，不少新兴生物技术公司也凭借创新药不断冒头。在这样的背景下，诺华收购Tourmaline Bio，一方面，是为了补充自身的管线。Tourmaline Bio的核心资产Pacibekitug是一款临床在研抗IL-6 IgG2人单抗，旨在通过高亲和力结合IL-6减轻与ASCVD有关的全身炎症，有望为诺华在心血管疾病治疗领域开拓新的方向。另一方面，通过收购，诺华或许能够整合Tourmaline Bio的技术，提升自身研发实力，增强在心血管疾病药物市场的竞争力，更好地应对竞争压力和专利到期带来的危机。而pacibekitug作为一种已处于临床后期阶段的资产，完美契合诺华的心血管战略布局。四、巨头的不同选择，"一弃一买" Tourmaline的科学创始人其实最早参与过辉瑞的IL-6项目，但当时辉瑞选择放弃继续开发这个靶点，转而把资源集中在其他优先领域。诺华却做出了完全不同的选择，这次收购也是诺华近期一系列战略动作的一部分，能看出公司对心血管和免疫学领域的重视和持续投入。从2024年到2025年，诺华两次与舶望制药达成合作，共同开发多款心血管siRNA疗法，潜在合作总额接近94亿美元。同时诺华也在加码神经科学领域，先是以超过8亿美元和BioArctic合作开发神经退行性疾病的新药，后来又花22亿美元引进了Arrowhead的一款治疗帕金森病的siRNA疗法。看得出来，诺华走的是一条差异化路线，没有盲目追逐热门的ADC或GLP-1赛道，而是绕过红海、开辟蓝海，深度布局核药、小核酸药物、细胞与基因治疗这些前沿方向。在核药领域，Pluvicto在2024年成为"重磅炸弹药物"；另一款核药Lutathera今年上半年销售额同比增长16%，达到4亿美元，也有潜力成为"十亿美元级"产品。这种战略差异并不说明哪家公司的策略更高明，更多是反映出大药企基于自身管线、财务和战略重点所做出的不同选择。诺华在剥离了仿制药业务山德士之后，变得更为专注和灵活，也更有能力和意愿去挖掘和培育那些需要耐心打磨的"璞玉"。五、Biotech的成功范式：独立验证价值后的高价并购 Tourmaline的发展路径，为生物技术公司提供了一个经典范本：先获得有潜力的资产，通过独立运营验证其科学价值，最后被大药企收购，借助其全球网络实现商业化。 Tourmaline虽然只有77名员工，却能够吸引诺华以14亿美元收购，最关键的就是通过严谨的临床试验证明了药物的价值和优势。从风险投资到上市，资本的支持让Tourmaline能够坚持研发直到数据读出。这次交易也给投资Tourmaline的资本带来了丰厚回报，验证了这一模式的成功，也会鼓励更多资金投入早期创新。这种"以并购为退出机制"的模式，对大多数Biotech来说其实是一个理想结局。这意味着它们的创新成果获得了市场的最终认可，未来也有机会借助大公司的资源帮助更多患者。近年来，大型药企通过并购获取创新药物和技术的现象愈发频繁，这一趋势在未来大概率还会持续。对于大型药企来说，并购是快速获取创新成果、补充管线、提升竞争力的有效途径。通过收购小型生物技术公司，大型药企可以将其创新技术和产品纳入自己的体系，缩短研发周期，降低研发风险。对于小型生物技术公司而言，并购浪潮既是机遇也是挑战。机遇在于它们可以获得更多的资金和资源支持，加速自身的发展；挑战在于可能会失去独立性，被大型药企整合后，原有的创新文化和研发方向可能会受到影响。结语 Pacibekitug最终的临床价值，还需要在三期临床试验和实际市场竞争中进一步验证。全球无数炎症性疾病患者，正在等待科学带来新的希望。随着这次收购的落地，制药行业对心血管领域创新的投资，很可能将迎来新一波热潮。参考信息： [1]https://www.novartis.com [2]https://bydrug.pharmcube.com/news/detail/53fb6220e78779680b32844c15806c61 [3]https://www.163.com/dy/article/K91EUOLA05568W0A.html [4]https://bydrug.pharmcube.com/news/detail/38d47f64e224e680337cc64a412c92e5 END 智药研习社近期直播预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

并购

2025-09-11

·PMLiVE

Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

Novartis has agreed to acquire Tourmaline Bio, a clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease. The cardiovascular treatment option will complement Novartis’ cardiovascular strategy by targeting IL-6, a key upstream cytokine that promotes systemic inflammation, thus addressing a critical unmet need. Phase 2 trials for pacibekitug are ongoing, meaning Novartis will acquire a phase 3-ready asset that will complement its existing cardiovascular disease portfolio. Shreeram Aradhye, President, Development and Chief Medical Officer, Novartis said: “Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. “With no widely adopted anti-inflammatory therapies currently available for cardiovascular risk reduction, pacibekitug represents a potential breakthrough in addressing residual inflammatory risk in ASCVD with a differentiated mechanism of action targeting IL-6”. The phase 2 TRANQUILITY 90-day study results were released this year in May, showing that pacibekitug reduced median high-sensitivity C-reactive protein (hs-CRP) levels by 85% through day 90 at a dose of 15 mg once monthly and by 86% at a dose of 50 mg delivered quarterly. Overall incidence rates of adverse events and serious adverse events were comparable to placebo. These results show the potential for pacibekitug to target residual inflammatory risk more effectively than current therapies, with a more convenient administration of once per quarter. Tourmaline Bio is valued at around $1.4bn, with an offer price of $48 per share, and the transaction is expected to close in the fourth quarter of 2025.

临床结果并购临床2期AHA会议

2025-09-10

·医药速览

诺华为了一款IL6单抗，14亿美元收购一家上市公司

9月9日，诺华宣布，已达成协议将收购Tourmaline Bio, Inc.，这是一家总部位于纽约的上市临床阶段生物制药公司。此次收购的核心是Tourmaline Bio正在开发的pacibekitug，这是一种抗IL-6单克隆抗体（mAb），旨在作为动脉粥样硬化性心血管疾病（ASCVD）的治疗方案。诺华此举旨在通过靶向IL-6，一种促进全身性炎症的关键上游细胞因子，补充其心血管战略，以解决ASCVD治疗中一个关键的未被满足的需求。 Pacibekitug是一种研究中的抗IL-6 IgG2人单克隆抗体，其设计目的是减轻与ASCVD相关的全身性炎症，并已证明对IL-6具有高亲和力结合。诺华开发和首席医疗官Shreeram Aradhye表示，炎症是心血管疾病的主要驱动因素，目前尚无广泛采用的抗炎疗法用于心血管风险的降低。他指出，pacibekitug以其靶向IL-6的差异化作用机制，代表着解决ASCVD患者残余炎症风险的潜在突破。 Pacibekitug的潜力在2期TRANQUILITY 90天研究结果中得到了显著体现，研究显示，每月一次15毫克剂量的pacibekitug使中位高敏感C反应蛋白（hs-CRP）水平降低了85%，而每季度一次50毫克剂量的pacibekitug则降低了86%。不良事件和严重不良事件的总发生率与安慰剂组相当。这些结果强调了pacibekitug通过更有效地靶向残余炎症风险，并提供方便的每季度一次给药来满足心血管护理中未满足需求的可能性。此次收购将使诺华获得一项已进入2期临床后期并准备进入3期临床的资产，从而进一步丰富其现有的心血管疾病产品组合。根据交易条款，诺华将通过其间接全资子公司发起要约收购Tourmaline的所有流通普通股。Tourmaline普通股持有人在交易完成时将获得每股48美元现金，此次交易对Tourmaline Bio的完全稀释估值约为14亿美元。此项交易已获得两家公司董事会的一致批准，预计将于2025年第四季度完成，但需满足惯例成交条件，包括多数流通股的要约以及获得监管批准。在交易完成之前，诺华和Tourmaline将继续作为独立公司运营。我们已经建立了医药交流群，群里有各大著名企业和重点高校的研究人员。大家可以一起讨论医药热点，分享经验，共同进步。想加入的话，扫码或添加小编微信（VX：chirouzhenxiang666），拉您进群！推文用于传递知识，如因版权等有疑问，请于本文刊发30日内联系医药速览。原创内容未经授权，禁止转载至其他平台。 ©2021 医药速览保留所有权利往期链接 “小小疫苗”养成记 | 医药公司管线盘点人人学懂免疫学| 人人学懂免疫学（语音版）综述文章解读 | 文献略读 | 医学科普|医药前沿笔记 PROTAC技术| 抗体药物| 抗体药物偶联-ADC 核酸疫苗 | CAR技术| 化学生物学温馨提示医药速览公众号目前已经有近12个交流群（好学，有趣且奔波于医药圈人才聚集于此）。进群请扫描上方二维码，备注“姓名/昵称-企业/高校-具体研究领域/专业”，此群仅为科研交流群，非诚勿扰。简单操作即可星标⭐️医药速览，第一时间收到我们的推送 ①点击标题下方“医药速览” ②至右上角“...” ③点击“设为星标

并购疫苗临床3期临床2期

100 项与 Pacibekitug 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床2期	美国	Tourmaline Bio, Inc.	2024-05-15
格雷夫斯眼病	临床2期	美国	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	加拿大	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	法国	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	意大利	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	约旦	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	拉脱维亚	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	新西兰	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	韩国	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	西班牙	Tourmaline Bio, Inc.	2024-02-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06362759 (TRANQUILITY, Company_Website) 人工标引	临床2期	慢性肾病	-	PacibekitugPacibekitug 25 mg quarterly	構網齋觸鬱積鹹膚壓鏇(顧積選選衊鬱齋餘願夢) = 齋網憲襯築壓繭憲廠鏇簾膚獵醖選簾艱淵廠窪 (艱窪積糧構積膚積齋淵 ) 更多	积极	2025-05-20
				PacibekitugPacibekitug 50 mg quarterly	構網齋觸鬱積鹹膚壓鏇(顧積選選衊鬱齋餘願夢) = 鏇膚鏇製艱構願衊膚獵簾膚獵醖選簾艱淵廠窪 (艱窪積糧構積膚積齋淵 ) 更多
NCT01287897 \| NCT01345318 (Pubmed \| Gut)	临床2期	克罗恩病	249	Placebo	鑰廠艱衊選淵衊積膚簾(製鬱範窪製觸淵糧醖繭) = 醖廠願繭醖願夢簾遞顧齋繭艱製簾選壓衊鏇遞 (鬱膚壓鑰襯鑰餘襯鏇製 ) 更多	-	2019-01-01
				PF-04236921 50mg	鑰廠艱衊選淵衊積膚簾(製鬱範窪製觸淵糧醖繭) = 鏇積簾壓選選網蓋構製齋繭艱製簾選壓衊鏇遞 (鬱膚壓鑰襯鑰餘襯鏇製 ) 更多
NCT01345318 (ANDANTE II \| B0151005, CTgov)	临床2期	克罗恩病	191	PF-04236921	遞襯壓製網蓋憲廠顧選 = 繭廠簾鹹網觸鹹蓋願窪選繭憲糧築壓顧齋積鑰 (鑰觸憲構醖鏇餘窪夢廠, 蓋築憲膚醖簾鹽齋網餘 ~ 顧壓蓋鹽願積廠選鏇構) 更多	-	2017-03-20
NCT01287897 (ANDANTE, ECCO2016)	临床2期	克罗恩病 CRP	247	PF-04236921 10 mg	築鑰繭簾夢壓廠遞膚鏇(廠糧糧顧製憲鬱願膚築) = 顧選齋構繭鬱廠網艱糧齋衊廠齋衊餘鹹繭膚壓 (範範網網範膚網顧膚遞 )	积极	2016-02-12
				PF-04236921 50 mg	製襯鹽淵構製淵積繭鹽(憲窪壓齋鑰簾鑰獵積襯) = 顧範壓製衊觸鏇壓鏇願憲餘壓獵鏇鹽夢範窪蓋 (構觸鏇簾蓋艱壓鏇簾鹽 ) 更多
NCT01287897 (ANDANTE, CTgov)	临床2期	克罗恩病	250	Placebo (Placebo)	鏇鏇憲蓋艱窪壓鑰簾鬱(蓋餘製簾壓壓鹽淵獵鏇) = 構鏇積艱積構壓壓鬱網糧膚選鏇襯蓋餘壓鏇鏇 (鏇繭憲壓選網築淵鏇鏇, 鏇齋衊鹽願製膚壓壓簾 ~ 淵壓膚窪鹽鏇築範鬱願) 更多	-	2016-01-21
				PF-04236921 (PF-04236921 10 mg)	鏇鏇憲蓋艱窪壓鑰簾鬱(蓋餘製簾壓壓鹽淵獵鏇) = 衊齋憲積網範鏇顧顧積糧膚選鏇襯蓋餘壓鏇鏇 (鏇繭憲壓選網築淵鏇鏇, 齋鬱選艱糧廠鏇遞廠襯 ~ 醖範願願艱鹹築繭顧獵) 更多